Treatment and outcome of Unicentric Castleman Disease: a retrospective analysis of 71 cases

被引：59

作者：

Boutboul, David ^{[1
,2
,3
,4
]}

Fadlallah, Jehane ^{[1
,4
]}

Chawki, Sylvain ^{[1
]}

Fieschi, Claire ^{[1
,4
,5
]}

Malphettes, Marion ^{[1
,6
]}

Dossier, Antoine ^{[7
]}

Gerard, Laurence ^{[1
,2
,6
]}

Mordant, Pierre ^{[4
,8
,9
]}

Meignin, Veronique ^{[2
,10
]}

Oksenhendler, Eric ^{[1
,2
,4
,6
]}

Galicier, Lionel ^{[1
,2
,6
]}

机构：

[1] Hop St Louis, AP HP, Dept Clin Immunol, Paris, France

[2] Univ Paris Diderot, Natl Reference Ctr Castleman Dis CRMdC, Paris, France

[3] Univ Paris Diderot, INSERM, CRI, UMR1149, Paris, France

[4] Univ Paris Diderot Paris 7, Paris, France

[5] Hop St Louis, Ctr Hayem, Inserm U1126, Paris, France

[6] Univ Paris Diderot Paris 7, EA3518, Paris, France

[7] Hop Bichat Claude Bernard, AP HP, Dept Internal Med, Paris, France

[8] Univ Paris Diderot Paris 7, Hop Bichat, INSERM, UMR S1152, Paris, France

[9] Hop Bichat Claude Bernard, Div Thorac & Vascu Surg, Paris, France

[10] Hop St Louis, AP HP, Dept Pathol, Paris, France

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2019年 / 186卷 / 02期

关键词：

Castleman disease; surgery; radiotherapy; watch-and-wait;

D O I：

10.1111/bjh.15921

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We retrospectively analysed 71 cases of Unicentric Castleman disease, a rare, usually asymptomatic, benign lymphoproliferative disorder presenting as a unique nodal mass. Although surgery is considered as the gold standard therapy, only 38 patients (54%) underwent initial surgical resection and 95% were cured. An additional 9 patients had surgery after an attempt at medical reduction. Reduction therapy was used in 21 patients with a 55% response rate, but without evidence for an optimal regimen. Radiotherapy was limited to 8 patients because of associated toxicity. Watch and wait was considered in 13 asymptomatic patients and 11 of these remained stable for up to 17 years.

引用

页码：269 / 273

页数：5

共 15 条

[1] Treatment of Unicentric Castleman Disease With Neoadjuvant Rituximab [J].

Bandera, Bradley ;

Ainsworth, Craig ;

Shikle, James ;

Rupard, Erik ;

Roach, Michael .

CHEST, 2010, 138 (05) :1239-1241

[2]

Bejjani J, 2009, CAN J SURG, V52, pE197

[3]

CASTLEMAN B, 1956, CANCER-AM CANCER SOC, V9, P822, DOI 10.1002/1097-0142(195607/08)9:4<822::AID-CNCR2820090430>3.0.CO

[4]

2-4

[5] Update and new approaches in the treatment of Castleman disease [J].

Chan, Kah-Lok ;

Lade, Stephen ;

Prince, H. Miles ;

Harrison, Simon J. .

JOURNAL OF BLOOD MEDICINE, 2016, 7 :145-158

[6]

Chronowski M, 2001, CANCER, V92, P670

[7] Outcome and late complications of radiotherapy in patients with unicentric Castleman disease [J].

Neuhof, Dirk ;

Debus, Juergen .

ACTA ONCOLOGICA, 2006, 45 (08) :1126-1131

[8] The full spectrum of Castleman disease: 273 patients studied over 20 years [J].

Oksenhendler, Eric ;

Boutboul, David ;

Fajgenbaum, David ;

Mirouse, Adrien ;

Fieschi, Claire ;

Malphettes, Marion ;

Vercellino, Laetitia ;

Meignin, Veronique ;

Gerard, Laurence ;

Galicier, Lionel .

BRITISH JOURNAL OF HAEMATOLOGY, 2018, 180 (02) :206-216

[9] Preoperative embolization as an adjunct to the operative management of mediastinal Castleman disease [J].

Safford, SD ;

Lagoo, AS ;

Mahaffey, SA .

JOURNAL OF PEDIATRIC SURGERY, 2003, 38 (09)

[10] Diagnosis and Management of Castleman Disease [J].

Soumerai, Jacob D. ;

Sohani, Aliyah R. ;

Abramson, Jeremy S. .

CANCER CONTROL, 2014, 21 (04) :266-278

← 1 2 →